BACKGROUND: @entity1166 ( @entity1166 ) is a polymorphic @entity1165 associated with @entity1162 . @entity1875 is a sedative-anesthetic with proarrhythmic effects on cardiac myocytes. We performed a retrospective study to determine the incidence of @entity1166 following @entity1875 exposure at Mayo Clinic (Rochester, MN) from 08/11/1998-11/20/2015. METHODS: We queried our database using key search terms to identify @entity1 exposed to @entity1875 who developed @entity1166 perioperatively or during non-surgical sedation. QT intervals were obtained from electrocardiograms (ECGs) performed before @entity1875 exposure and after documented @entity1166 and were corrected using Fridericia and Framingham methods. T wave peak-to-end (Tp-e)/QT ratios were also calculated. RESULTS: A total of 628,784 @entity1 received @entity1875 over 17.3years. Of these @entity1 , 21 developed @entity1166 (12, postoperatively; 3, intraoperatively; 6, during sedation). There were 17 @entity1 who were exposed to at least one factor associated with @entity1162 , including @entity1162 medications in 8 @entity1 , heart rate <60 beats per minute in 8 @entity1 , @entity972 <3.5mmol/L in 4 @entity1 , @entity1760 <1.8mg/dL in 2 @entity1 , and @entity510 in 2 @entity1 . The number of @entity1 with QTc>500ms using Fridericia correction was significantly higher from baseline following exposure to @entity1875 (1 @entity1 vs 6 @entity1 , P=0.04); however no significant difference was observed with Framingham correction. CONCLUSION: In our study, @entity1166 after @entity1875 administration occurred with an annual incidence of 1.93 per million and was often associated with other risk factors. Nevertheless, @entity1875 should be administered with caution in @entity1 at risk of developing @entity1166 .

The possible role of @entity1875 in drug-induced XXXX : A real-world single-center analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia'] @entity1166 :: ('MESH:D016171', 'Disease') :: ['TdP', 'Torsades de pointes'] @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage'] @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity1162 :: ('MESH:D008133', 'Disease') :: ['QT-prolongation', 'QT-prolonging', 'QT prolongation'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity1166 :: (MESH:D016171,Disease) :: ['torsades de pointes']
